Compare Ascendis Pharma A/S (ASND) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Open Text Corporation — how do they compare? Ascendis Pharma A/S trades at $255.85 (market cap $16.67B), while Open Text Corporation trades at $23.54 (market cap $5.80B). The key difference: Ascendis Pharma A/S is far larger — about 2.9× Open Text Corporation's market cap, and Open Text Corporation pays a 4.67% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | OTEX | |
|---|---|---|
Market Cap | $16.67B | $5.80B |
Sector | Health | Technology |
52-Week High | $277.18 | $39.69 |
52-Week Low | $189.74 | $20.01 |
Enterprise Value | $17.04B | $10.81B |
Dividend Yield | — | 4.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Open Text Corporation (OTEX) trades at $23.27, down 5.87% over the past day, with a bullish technical signal despite recent weakness. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.23 versus $1.02 expected, and maintains solid fundamentals including a 73.74% gross margin and 12.26% net income margin. Recent news highlights cloud revenue growth and a $105 million AI investment in Europe.
Outlook remains positive with a consensus price target of $29.33 implying 26% upside, supported by earnings beats and strategic AI investments. Risks include high debt levels and competitive pressures in the software sector. The stock offers value with a P/E of 9.29 and a 4.7% dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
